A recent two-sample Mendelian randomization in 547 261– 977 323 individuals concluded that elevated plasma adiponectin may be causally associated with reduced risk of coronary artery disease but not with heart failure and atrial fibrillation.53 However, only one of four statistical methods could support the potential causal finding. Here, ADIPOQ is linked to heart failure.